A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 31, 2018

Study Completion Date

December 31, 2018

Conditions

Glioblastoma Multiforme

Interventions

DRUG

axitinib

The starting dose of axitinib (AG-013736) is 5 mg BID administered orally with food.

DRUG

Axitinib plus Lomustine

Lomustine 90mg/m²

Trial Locations (1)

UZ Brussel, Brussels